Compare · HYZN vs TMO
HYZN vs TMO
Side-by-side comparison of Hyzon Motors Inc. (HYZN) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- HYZN operates in Energy, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $257.53B, about 222.2x HYZN ($1.16B).
- TMO has hit the wire 7 times in the past 4 weeks while HYZN has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 12 for HYZN).
- Company
- Hyzon Motors Inc.
- Thermo Fisher Scientific Inc
- Price
- $0.67+31.55%
- $690.13-0.92%
- Market cap
- $1.16B
- $257.53B
- 1M return
- -
- +4.77%
- 1Y return
- -
- +28.01%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 7
- Recent ratings
- 12
- 25
Hyzon Motors Inc.
HYZON Motors Inc, a hydrogen mobility company, manufactures hydrogen-powered commercial vehicles and fuel cell systems. It focuses on developing medium and heavy-duty trucks, as well as city and coach buses. The company was incorporated in 2020 and is headquartered in Honeoye Falls, New York.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest HYZN
- Hyzon Announces Stockholder Approval of Assignment Proposal and Dissolution Proposal
- HYZON ANNOUNCES DELISTING FROM NASDAQ AND EXPECTED SEC DEREGISTRATION
- SEC Form 424B3 filed by Hyzon Motors Inc.
- Hyzon Motors Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 424B3 filed by Hyzon Motors Inc.
- Hyzon Motors Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 424B3 filed by Hyzon Motors Inc.
- Hyzon Motors Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- GC & Chief Legal Officer Zavoli John R converted options into 638 shares and sold 320 shares (SEC Form 4)
- SEC Form 424B3 filed by Hyzon Motors Inc.
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)